Lung Cancer Trials Ask AI to find trials
CompletedPhase 2NCT02179671
Official study title

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Study summary

Primary objective: To assess the efficacy of various sequences of either a small molecule or an IMT (IMT-A) followed by a IMT-B (MEDI4736) .

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedGefitinib and AZD9291

Plus 2 other study approaches.

Who it may be forLocally advanced · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 2, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?10 U.S. locations

Locations may change over time.

Who runs it?AstraZeneca

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
AstraZeneca
Interventions being studied
Drug: Gefitinib; Drug: AZD9291; Drug: Selumetinib+Docetaxel; Drug: Tremelimumab
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Locally advanced→Metastatic or stage IV→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Provision of archived tumor tissue sample and mandatory tissue biopsy
  • Patients must have either histologically or cytologically documented NSCLC who present with locally advanced or metastatic stage IIIB-IV disease
  • Life expectancy ≥12 weeks
  • Patients must have measurable disease and at least 1 lesion not previously irradiated
  • World Health Organization (WHO) performance status of 0 or 1
Reasons someone may not be able to joinExclusion criteria
  • Mixed small cell and NSCLC histology
  • Prior exposure to any anti-PD-1 or anti-PD-L1 antibody

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Research SiteGoodyear, Arizona
  • Research SiteWashington D.C., District of Columbia
  • Research SiteAugusta, Georgia
  • Research SiteMarietta, Georgia
  • Research SiteAshland, Kentucky
  • Research SiteSt Louis, Missouri
  • Research SiteMineola, New York
  • Research SiteHuntersville, North Carolina
  • Research SiteSpokane, Washington
  • Research SiteTacoma, Washington

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 2, 2019. Always confirm current availability with the study team.

View original record ↗